|
1
|
Silva-Filho AL, Carmo GA, Athayde GR,
Assis ME, Almeida RC, Leal RH, Lamaita RM, Santos-Júnior JL and
Castro e Silva JG: Safe fertility-preserving management in
gynecological malignancies. Arch Gynecol Obstet. 275:321–330. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3
|
Dorigo O and Berek JS: Personalizing CA125
levels for ovarian cancer screening. Cancer Prev Res (Phila).
4:1356–1359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brewer MA, Johnson K, Follen M, Gershenson
D and Bast R Jr: Prevention of ovarian cancer: intraepithelial
neoplasia. Clin Cancer Res. 9:20–30. 2003.PubMed/NCBI
|
|
5
|
Roett MA and Evans P: Ovarian cancer: an
overview. Am Fam Physician. 80:609–616. 2009.
|
|
6
|
Feeley KM and Wells M: Precursor lesions
of ovarian epithelial malignancy. Histopathology. 38:87–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dubeau L: The cell of origin of ovarian
epithelial tumours. Lancet Oncol. 9:1191–1197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berek JS, Chalas E, Edelson M, Moore DH,
Burke WM, Cliby WA and Berchuck A; Society of Gynecologic
Oncologists Clinical Practice Committee. Prophylactic and
risk-reducing bilateral salpingo-oophorectomy: recommendations
based on risk of ovarian cancer. Obstet Gynecol. 116:733–743. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pal T, Permuth-Wey J and Sellers TA: A
review of the clinical relevance of mismatch-repair deficiency in
ovarian cancer. Cancer. 113:733–742. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sidransky D: Emerging molecular markers of
cancer. Nat Rev Cancer. 2:210–219. 2002. View Article : Google Scholar
|
|
11
|
Sood AK, Holmes R, Hendrix MJ and Buller
RE: Application of the National Cancer Institute international
criteria for determination of microsatellite instability in ovarian
cancer. Cancer Res. 61:4371–4374. 2001.PubMed/NCBI
|
|
12
|
Singer G, Kallinowski T, Hartmann A,
Dietmaier W, Wild PJ, Schraml P, Sauter G, Mihatsch MJ and Moch H:
Different types of microsatellite instability in ovarian carcinoma.
Int J Cancer. 112:643–646. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fathalla MF: Incessant ovulation-a factor
in ovarian neoplasia? Lancet. 2:1631971. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Massey A, Offman J, Macpherson P and
Karran P: DNA mismatch repair and acquired cisplatin resistance in
E. coli and human ovarian carcinoma cells. DNA Repair
(Amst). 2:73–89. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crijnen TE, Janssen-Heijnen ML, Gelderblom
H, Morreau J, Nooij MA, Kenter GG and Vasen HF: Survival of
patients with ovarian cancer due to a mismatch repair defect. Fam
Cancer. 4:301–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lawes DA, SenGupta S and Boulos PB: The
clinical importance and prognostic implications of microsatellite
instability in sporadic cancer. Eur J Surg Oncol. 29:201–212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vaughn CP, Lyon E and Samowitz WZ:
Confirmation of single exon deletions in MLH1 and MSH2 using
quantitative polymerase chain reaction. J Mol Diagn. 10:355–360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Y, Liu XS, Wang YX, Song HY and Zhong
N: Study of microsatellite instability in epithelial ovarian
tumors. Beijing Da Xue Xue Bao. 38:62–65. 2006.PubMed/NCBI
|
|
20
|
Yoon BS, Kim YT, Kim JH, Kim SW, Nam EJ,
Cho NH, Kim JW and Kim S: Clinical significance of microsatellite
instability in sporadic epithelial ovarian tumors. Yonsei Med J.
49:272–278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gryfe R, Kim H, Hsieh ET, Aronson MD,
Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor
microsatellite instability and clinical outcome in young patients
with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau
SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R,
Shepherd LE, Tu D, Redston M and Gallinger S: Tumor
microsatellite-instability status as a predictor of benefit from
fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J
Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakamoto-Hojo ET and Balajee AS: Targeting
poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting
proteins for cancer treatment. Anticancer Agents Med Chem.
8:402–416. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murphy MA and Wentzensen N: Frequency of
mismatch repair deficiency in ovarian cancer: a systematic review.
International Journal of Cancer. 129:1914–1922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guppy AE, Nathan PD and Rustin GJ:
Epithelial ovarian cancer: a review of current management. Clin
Oncol (R Coll Radiol). 17:399–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
